# EDGAR Filing Document

**Accession Number:** 0001528172
**File Stem:** 0001493152-23-010206
**Filing Date:** 2023-3
**Character Count:** 8270
**Document Hash:** dfedaa2356e1da8f55ed8b928b613413
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-010206.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001493152-23-010206

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENDONOVO THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001528172
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 452552528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55453
- **FILM NUMBER:** 23787282

**BUSINESS ADDRESS:**
- **STREET 1:** 6320 CANOGA AVENUE
- **STREET 2:** 15TH FLOOR
- **CITY:** WOODLAND HILLS
- **STATE:** CA
- **ZIP:** 91367
- **BUSINESS PHONE:** (800) 489-4774

**MAIL ADDRESS:**
- **STREET 1:** 6320 CANOGA AVENUE
- **STREET 2:** 15TH FLOOR
- **CITY:** WOODLAND HILLS
- **STATE:** CA
- **ZIP:** 91367

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hanover Portfolio Acquisitions, Inc.
- **DATE OF NAME CHANGE:** 20110920

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hanover Portfoliio Acquisitions, Inc.
- **DATE OF NAME CHANGE:** 20110817

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

| | |
|:---|:---|
| **FORM 12b-25** | SEC FILE NUMBER |
|  | **000-55453** |
|  | CUSIP NUMBER |
| **NOTIFICATION OF LATE FILING** | **29272H 201** |

---

(Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

For Period Ended: <u>December 31, 2022</u>

---

| | |
|:---|:---|
| ☐ | Transition Report on Form 10-K |
| ☐ | Transition Report on Form 20-F |
| ☐ | Transition Report on Form 11-K |
| ☐ | Transition Report on Form 10-Q |
| ☐ | Transition Report on Form N-SAR |
| For the Transition Period Ended: _________________ | For the Transition Period Ended: _________________ |

---

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

---

| |
|:---|
| **ENDONOVO THERAPEUTICS, INC.** |
| Full Name of Registrant |
| Former Name if Applicable |
| 6320 CANOGA AVENUE, 15<sup>th</sup> FLOOR |
| Address of Principal Executive Office *(Street and Number)* |
| WOODLAND HILLS, CA 91367 |
| City, State and Zip Code |

---

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The
 subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
 thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
 or transition report on Form 10-Q or subject distribution report on Form 10-D or portion thereof, will be filed on or before the
 fifth calendar day following the prescribed due date; and

(c) The
 accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

---

| |
|:---|
| PART III — NARRATIVE |
| State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed) |
| Endonovo Therapeutics, Inc. (the "Company") is not in a position to file its Annual Report on Form 10-K for the period ended December 31, 2022 (the "Form 10-K") in a timely manner because the Company cannot complete the Form 10-K in a timely manner without unreasonable effort or expense. As a result, the Company is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its audit of the consolidated financial statements for the year ended December 31, 2022, to be incorporated in the Annual Report. The Company intends to file its Annual Report on Form 10-K no later than the fifteenth calendar day following the prescribed due date. |

---

PART IV — OTHER INFORMATION

---

| | | | |
|:---|:---|:---|:---|
| (1) | Name and telephone number of person to contact in regard to this notification | Name and telephone number of person to contact in regard to this notification | Name and telephone number of person to contact in regard to this notification |
|  | Alan Collier | (800) | 489-4774 |
|  | (Name) | (Area Code) | (Telephone Number) |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). |
| Yes ☒ No ☐ | Yes ☒ No ☐ | Yes ☒ No ☐ | Yes ☒ No ☐ |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
| Yes ☐ No ☒ | Yes ☐ No ☒ | Yes ☐ No ☒ | Yes ☐ No ☒ |
|  | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |

---

---

| | | |
|:---|:---|:---|
| **ENDONOVO THERAPEUTICS, INC.** | **ENDONOVO THERAPEUTICS, INC.** | **ENDONOVO THERAPEUTICS, INC.** |
| (Name of Registrant as Specified in Charter) | (Name of Registrant as Specified in Charter) | (Name of Registrant as Specified in Charter) |
| has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. | has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. | has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. |
| March 31, 2023 | By: | /s/ *Alan Collier* |
|  |  | Alan Collier, Chairman and Chief Executive Officer |

---

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).